DE3116733A1 - Mittel und verfahren zur behandlung von krebs - Google Patents
Mittel und verfahren zur behandlung von krebsInfo
- Publication number
- DE3116733A1 DE3116733A1 DE19813116733 DE3116733A DE3116733A1 DE 3116733 A1 DE3116733 A1 DE 3116733A1 DE 19813116733 DE19813116733 DE 19813116733 DE 3116733 A DE3116733 A DE 3116733A DE 3116733 A1 DE3116733 A1 DE 3116733A1
- Authority
- DE
- Germany
- Prior art keywords
- brain tissue
- tissue
- cancer
- treatment
- mammalian
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 206010028980 Neoplasm Diseases 0.000 title claims description 49
- 201000011510 cancer Diseases 0.000 title claims description 40
- 238000000034 method Methods 0.000 title description 8
- 238000011282 treatment Methods 0.000 claims description 48
- 210000001519 tissue Anatomy 0.000 claims description 29
- 108010034634 Repressor Proteins Proteins 0.000 claims description 22
- 102000009661 Repressor Proteins Human genes 0.000 claims description 18
- 210000005013 brain tissue Anatomy 0.000 claims description 18
- 239000000725 suspension Substances 0.000 claims description 8
- 210000000944 nerve tissue Anatomy 0.000 claims description 7
- 241000283690 Bos taurus Species 0.000 claims description 6
- 241000283073 Equus caballus Species 0.000 claims description 4
- 241000124008 Mammalia Species 0.000 claims description 3
- 241000288906 Primates Species 0.000 claims description 3
- 241001398967 Colonia Species 0.000 claims description 2
- 210000005171 mammalian brain Anatomy 0.000 claims 6
- 239000000203 mixture Substances 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 51
- 108090000623 proteins and genes Proteins 0.000 description 34
- 239000003795 chemical substances by application Substances 0.000 description 14
- 108020004414 DNA Proteins 0.000 description 12
- 241000699800 Cricetinae Species 0.000 description 10
- 102000004169 proteins and genes Human genes 0.000 description 10
- 238000011161 development Methods 0.000 description 9
- 230000018109 developmental process Effects 0.000 description 9
- 201000010099 disease Diseases 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 230000002068 genetic effect Effects 0.000 description 8
- 108700005075 Regulator Genes Proteins 0.000 description 7
- 230000000973 chemotherapeutic effect Effects 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 6
- 230000003211 malignant effect Effects 0.000 description 6
- 239000012528 membrane Substances 0.000 description 6
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 238000002512 chemotherapy Methods 0.000 description 5
- 108010074605 gamma-Globulins Proteins 0.000 description 5
- 230000035699 permeability Effects 0.000 description 5
- 241000894006 Bacteria Species 0.000 description 4
- 108060003951 Immunoglobulin Proteins 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 4
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 4
- 102000018358 immunoglobulin Human genes 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- 108020004999 messenger RNA Proteins 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 230000003439 radiotherapeutic effect Effects 0.000 description 4
- 238000001959 radiotherapy Methods 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 4
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 3
- 102000053602 DNA Human genes 0.000 description 3
- 206010027476 Metastases Diseases 0.000 description 3
- 208000036142 Viral infection Diseases 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 208000009956 adenocarcinoma Diseases 0.000 description 3
- 210000003855 cell nucleus Anatomy 0.000 description 3
- 229910052740 iodine Inorganic materials 0.000 description 3
- 239000011630 iodine Substances 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 230000009401 metastasis Effects 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 230000035897 transcription Effects 0.000 description 3
- 238000013518 transcription Methods 0.000 description 3
- 238000013519 translation Methods 0.000 description 3
- 230000009385 viral infection Effects 0.000 description 3
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 2
- 229930024421 Adenine Natural products 0.000 description 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- 201000009030 Carcinoma Diseases 0.000 description 2
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 2
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 2
- 101710088194 Dehydrogenase Proteins 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 229960000643 adenine Drugs 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- 229940104302 cytosine Drugs 0.000 description 2
- 230000008034 disappearance Effects 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 210000005075 mammary gland Anatomy 0.000 description 2
- 231100000590 oncogenic Toxicity 0.000 description 2
- 230000002246 oncogenic effect Effects 0.000 description 2
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 229940113082 thymine Drugs 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- ASJSAQIRZKANQN-CRCLSJGQSA-N 2-deoxy-D-ribose Chemical compound OC[C@@H](O)[C@@H](O)CC=O ASJSAQIRZKANQN-CRCLSJGQSA-N 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 235000019687 Lamb Nutrition 0.000 description 1
- 208000035415 Reinfection Diseases 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 239000003124 biologic agent Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000013043 chemical agent Substances 0.000 description 1
- 231100000481 chemical toxicant Toxicity 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000008260 defense mechanism Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 210000004324 lymphatic system Anatomy 0.000 description 1
- 208000037819 metastatic cancer Diseases 0.000 description 1
- 208000011575 metastatic malignant neoplasm Diseases 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Ophthalmology & Optometry (AREA)
- Zoology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14541980A | 1980-05-01 | 1980-05-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE3116733A1 true DE3116733A1 (de) | 1982-04-01 |
Family
ID=22513026
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE19813116733 Withdrawn DE3116733A1 (de) | 1980-05-01 | 1981-04-28 | Mittel und verfahren zur behandlung von krebs |
Country Status (8)
| Country | Link |
|---|---|
| JP (1) | JPS5874615A (OSRAM) |
| CA (1) | CA1175741A (OSRAM) |
| CH (1) | CH655659B (OSRAM) |
| DE (1) | DE3116733A1 (OSRAM) |
| ES (1) | ES501835A0 (OSRAM) |
| FR (1) | FR2481602A1 (OSRAM) |
| GB (1) | GB2075988B (OSRAM) |
| MX (1) | MX6826E (OSRAM) |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2717227A (en) * | 1954-12-22 | 1955-09-06 | Helen L Dawson | Composition containing nerve tissue extract and process of producing such extract |
| DE1095464B (de) * | 1956-05-22 | 1960-12-22 | Univ Tulane | Verfahren zur Herstellung eines Heilmittels zur Behandlung von Schizophrenie und anderen Geisteskrankheiten |
-
1981
- 1981-04-28 DE DE19813116733 patent/DE3116733A1/de not_active Withdrawn
- 1981-04-29 FR FR8108520A patent/FR2481602A1/fr active Granted
- 1981-04-30 GB GB8113341A patent/GB2075988B/en not_active Expired
- 1981-04-30 MX MX819434U patent/MX6826E/es unknown
- 1981-04-30 ES ES501835A patent/ES501835A0/es active Granted
- 1981-05-01 CH CH286381A patent/CH655659B/de not_active IP Right Cessation
- 1981-10-22 CA CA000388472A patent/CA1175741A/en not_active Expired
- 1981-10-30 JP JP56174406A patent/JPS5874615A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| ES8300477A1 (es) | 1982-11-01 |
| ES501835A0 (es) | 1982-11-01 |
| JPS5874615A (ja) | 1983-05-06 |
| GB2075988B (en) | 1983-09-01 |
| MX6826E (es) | 1986-08-08 |
| GB2075988A (en) | 1981-11-25 |
| FR2481602A1 (fr) | 1981-11-06 |
| CA1175741A (en) | 1984-10-09 |
| CH655659B (OSRAM) | 1986-05-15 |
| FR2481602B1 (OSRAM) | 1984-06-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2003035868A1 (de) | Medikament zur erhöhung der wirksamkeit eines rezeptor-vermittelt apoptose in tumorzellen auslösenden arzeimittels | |
| DE2902136A1 (de) | Interferon und es enthaltende zubereitungen | |
| DE69106656T2 (de) | Tanninextrakt von Kastanienholz, Verfahren zu deren Herstellung und deren Verwendung. | |
| Farrell | Fine structure of nerve fibres in smooth muscle of the vas deferens in normal and reserpinized rats | |
| DE3115080A1 (de) | Arzneimittel fuer die orale verabreichung und verfahren zu seiner herstellung | |
| EP1056467A2 (de) | Verfahren zur behandlung von erkrankungen oder störungen des innenohrs | |
| DE1017744B (de) | Verfahren zur Gewinnung von wachstumsfoerdernden Stoffen fuer therapeutische Zwecke | |
| DE3884853T2 (de) | Angiogenininhibitoren. | |
| DE3116733A1 (de) | Mittel und verfahren zur behandlung von krebs | |
| DE60029117T2 (de) | DNA Sequenzen zur Erhöhung der Futterausbeute und der Wachstumsrate bei Schweinen | |
| DE60216292T2 (de) | Calciumtrifluoracetat mit zytotoxischer wirkung | |
| DE2352662A1 (de) | Verfahren zur herstellung eines uebertragungsfaktors | |
| DE69432444T2 (de) | Promotor-Sequenz des Rezeptors p55 für Tumor-Nekrosis-Faktor | |
| DE1086012B (de) | Verfahren zur Herstellung von protrahiert wirkenden Vitamin-B-Praeparaten | |
| DE3524794A1 (de) | Pharmazeutisches praeparat enthaltend lebende vermehrungsfaehige embryonalzellen, verfahren zu dessen herstellung und testverfahren zur bestimmung der pharmazeutischen wirksamkeit | |
| DE69432042T2 (de) | Verfahren zum Screenen von Agenzien zur Prophylaxis oder Therapie von mit IgE zusammenhängenden Krankheiten | |
| DE1617538C3 (de) | Verfahren zur Herstellung von Tetanus-Antitoxin | |
| AT70271B (de) | Verfahren zur Herstellung eines Serums gegen Gonorrhoe. | |
| DE19828624C1 (de) | Modular aufgebaute RNA-Moleküle mit zwei Sequenzbereichstypen | |
| DE216310C (OSRAM) | ||
| EP1608355A2 (de) | Verwendung von nep-assoziierten molek len zur behandlung von nichtimmunogenen-nichthypertensiven zivilisationskrankheiten | |
| DE2722769C3 (de) | Verwendung von Fibrinogen | |
| AT92081B (de) | Verfahren zur Herstellung von avirulenten Heil- und Schutzstoffen für Tuberkulose. | |
| AT10535B (de) | Verfahren zur Herstellung eines Heilserums gegen Zuckerkrankheit. | |
| DE202023103094U1 (de) | Ein System zur Regeneration menschlicher Zellen mit isoliertem regenerativem Gen eines Planarienorganismus |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8128 | New person/name/address of the agent |
Representative=s name: TUERK, D., DIPL.-CHEM. DR.RER.NAT. GILLE, C., DIPL |
|
| 8141 | Disposal/no request for examination |